BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 27306997)

  • 1. Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index.
    Lee HE; Mounajjed T; Erickson LA; Wu TT
    Endocr Pathol; 2016 Sep; 27(3):259-67. PubMed ID: 27306997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
    Özaslan E; Demir S; Karaca H; Güven K
    Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Subtype classification and clinicopathological characteristics of gastric neuroendocrine neoplasms: an analysis of 241 cases].
    Zhang P; Zhang Y; Zhang C; Shi Y; Liu J; Liu Q; Yu L; Wang M; Zou G; Lou J; Chen J; Tan H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1241-1246. PubMed ID: 27928793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
    Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
    Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
    Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
    World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary renal well-differentiated neuroendocrine tumors: report of six cases with an emphasis on the Ki-67 index and mitosis.
    Kim B; Kim HS; Moon KC
    Diagn Pathol; 2019 Feb; 14(1):12. PubMed ID: 30732641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Evaluations Tailored to Specific Gastric Neuroendocrine Neoplasms: Analysis Of 200 Cases with Extended Follow-Up.
    Vanoli A; La Rosa S; Miceli E; Klersy C; Maragliano R; Capuano F; Persichella A; Martino M; Inzani F; Luinetti O; Di Sabatino A; Sessa F; Paulli M; Corazza GR; Rindi G; Bordi C; Capella C; Solcia E
    Neuroendocrinology; 2018; 107(2):114-126. PubMed ID: 29895024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
    Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
    McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
    Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathologic characteristics and prognosis of rectal neuroendocrine neoplasms].
    Liu T; Liu P; Wu T; Pan Y; Chen G; Wang P; Jiang Y; Wu Y; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1015-1019. PubMed ID: 28900992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors.
    Dhall D; Mertens R; Bresee C; Parakh R; Wang HL; Li M; Dhall G; Colquhoun SD; Ines D; Chung F; Yu R; Nissen NN; Wolin E
    Hum Pathol; 2012 Apr; 43(4):489-95. PubMed ID: 21937080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Improved Prognostic Stratification With the New World Health Organization 2019 Classification: A Validation Study From a Single-Institution Retrospective Analysis.
    Hayes AR; Furnace M; Shah R; Rundell C; Muller G; Dehbi HM; Luong TV; Toumpanakis C; Caplin ME; Krell D; Thirlwell C; Mandair D
    Pancreas; 2021 Apr; 50(4):516-523. PubMed ID: 33939663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
    Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinicopathologic features and prognostic analysis of 240 patients with gastric neuroendocrine neoplasms].
    Liang WQ; Zhang W; Qiao S; Wang BH; Wang C; Zhuang ZW; Xi HQ; Cai AZ; Wei B; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):38-43. PubMed ID: 31958929
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinicopathological Features of Primary Neuroendocrine Tumors of Gastrointestinal/Pancreatobiliary Tract With Emphasis on High-Grade (Grade 3) Well-Differentiated Neuroendocrine Tumors.
    Hashmi AA; Ali J; Yaqeen SR; Ahmed O; Asghar IA; Irfan M; Asif MG; Edhi MM; Hashmi S
    Cureus; 2021 Jan; 13(1):e12640. PubMed ID: 33585126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.